Top

Published in:

01-04-2017 | Original Article

Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody-eliciting capacity and is suitable for the establishment of a recombinant vaccine

Authors: Kiyohiko Andoh, Kenichi Yamazaki, Yoko Honda, Takashi Honda

Published in: Archives of Virology | Issue 4/2017

Abstract

We constructed turkey herpesvirus (HVT) vector vaccines in which the VP2 gene of infectious bursal disease virus (IBDV) was inserted into the HVT genome in the following regions: UL3-4, UL22-23, UL45-46, and US10-SORF3. We then evaluated the relationship between the gene insertion site and the capacity of the virus to elicit antibodies. rHVT/IBD (US10) showed good growth activity in vitro, with growth comparable to that of the parent HVT. On the other hand, rHVT/IBD (UL3-4), rHVT/IBD (UL22-23), and rHVT/IBD (UL45-46) exhibited decreased growth activity in chicken embryo fibroblast (CEF) cells compared to the parent HVT. However, the rHVT/IBD (US10) elicited lower levels of virus-neutralizing (VN) antibodies compared to the other constructs. rHVT/IBD (UL3-4) and rHVT/IBD (UL45-46) appeared to be similar in their ability to elicit VN antibodies. Based on the results of in vitro and in vivo assays, rHVT/IBD (UL3-4) was selected for further testing. In a challenge assay, rHVT/IBD (UL3-4) protected chickens from challenge with virulent Marek’s disease virus serotype 1 and IBDV. In conclusion, the site of gene insertion may have a strong effect on the growth of the vector virus in vitro and its antibody-eliciting capacity. Insertions in the UL3-4 region permitted a balance between growth activity and VN-antibody-eliciting capacity, and this region might therefore be an appropriate insertion site for IBDV VP2.

Available only for authorised users

Afonso CL, Tulman ER, Lu Z et al (2001) The genome of turkey herpesvirus. J Virol 75(2):971–978. doi:10.1128/JVI.75.2.971-978.2001 CrossRefPubMedPubMedCentral

Baigent SJ, Smith LP, Currie RJ, Nair VK (2007) Correlation of Marek’s disease herpesvirus vaccine virus genome load in feather tips with protection, using an experimental challenge model. Avian Pathol 36(6):467–474. doi:10.1080/03079450701639319 CrossRefPubMed

Bublot M, Laplace E, Audonnet JC (1999) Non-essential loci in the BamHI-I and -F fragments of the HVT FC126 genome. Acta Virol 43(2–3):181–185PubMed

Bublot M, Pritchard N, Le Gros FX, Goutebroze S (2007) Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternally derived antibody. J Comp Pathol 137(1):S81–S84. doi:10.1016/j.jcpa.2007.04.017 CrossRefPubMed

Cui H, Gao H, Cui X et al (2013) Avirulent Marek’s disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine. PLoS One 8(1):e53340. doi:10.1371/journal.pone.0053340 CrossRefPubMedPubMedCentral

Darteil R, Bublot M, Laplace E et al (1995) Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology 211(2):481–490. doi:10.1006/viro.1995.1430 CrossRefPubMed

Esaki M, Godoy A, Rosenberger JK et al (2013) Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine. Avian Dis 57(4):750–755. doi:10.1637/10540-032613-Reg.1 CrossRefPubMed

Esaki M, Noland L, Eddins T et al (2013) Safety and efficacy of a turkey herpesvirus vector laryngotracheitis vaccine for chickens. Avian Dis 57(2):192–198. doi:10.1637/10383-092412-Reg.1 CrossRefPubMed

Fahey KJ, Erny K, Crooks J (1989) A conformational immunogen on VP-2 of infectious bursal disease virus that induces virusneutralizing antibodies that passively protect chickens. J Gen Virol 70(6):1473–1481. doi:10.1099/0022-1317-70-6-1473 CrossRefPubMed

10.

Gao H, Cui H, Cui X et al (2011) Expression of HA of HPAI H5N1 virus at US2 gene insertion site of turkey herpesvirus induced better protection than that at US10 gene insertion site. PLoS One 6(7):e22549. doi:10.1371/journal.pone.0022549 CrossRefPubMedPubMedCentral

11.

Gimeno IM (2008) Marek’s disease vaccines: a solution for today but a worry for tomorrow? Vaccine 26(Suppl 3):C31–C41. doi:10.1016/j.vaccine.2008.04.009 CrossRefPubMed

12.

Gimeno IM, Cortes AL, Faiz N et al (2016) Efficacy of various HVT vaccines (conventional and recombinant) against Marek’s disease in broiler chickens: effect of dose and age of vaccination. Avian Dis 60(3):662–668. doi:10.1637/11415-040116-Reg.1 CrossRefPubMed

13.

Hall RN, Meers J, Fowler EV, Mahony TJ (2015) Identification of non-essential loci within the Meleagrid herpesvirus 1 genome. Virol J 12:130. doi:10.1186/s12985-015-0362-9 CrossRefPubMedPubMedCentral

14.

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458. doi:10.1038/bmt.2012.244 CrossRefPubMed

15.

Kibenge FS, Dhillon AS, Russell RG (1988) Biochemistry and immunology of infectious bursal disease virus. J Gen Virol 69(8):1757–1775. doi:10.1099/0022-1317-69-8-1757 CrossRefPubMed

16.

Ma C, Zhang Z, Zhao P et al (2014) Comparative transcriptional activity of five promoters in BAC-cloned MDV for the expression of the hemagglutinin gene of H9N2 avian influenza virus. J Virol Methods 206:119–127. doi:10.1016/j.jviromet.2014.05.023 CrossRefPubMed

17.

Macreadie IG, Vaughan PR, Chapman AJ et al (1990) Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast. Vaccine 8(6):549–552. doi:10.1016/0264-410X(90)90006-8 CrossRefPubMed

18.

Mahgoub HA, Bailey M, Kaiser P (2012) An overview of infectious bursal disease. Arch Virol 157(11):2047–2057. doi:10.1007/s00705-012-1377-9 CrossRefPubMed

19.

Mahony TJ, Hall RN, Walkden-Brown S et al (2015) Genomic deletions and mutations resulting in the loss of eight genes reduce the in vivo replication capacity of Meleagrid herpesvirus 1. Virus Genes 51(1):85–95. doi:10.1007/s11262-015-1216-7 CrossRefPubMed

20.

Morgan RW, Gelb J Jr, Schreurs CS et al (1992) Protection of chickens from Newcastle and Marek’s diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein. Avian Dis 36(4):858–870. doi:10.2307/1591544 CrossRefPubMed

21.

Muskett JC, Hopkins IG, Edwards KR, Thornton DH (1979) Comparison of two infectious bursal disease vaccine strains: efficacy and potential hazards in susceptible and maternally immune birds. Vet Rec 104(15):332–334. doi:10.1136/vr.104.15.332 CrossRefPubMed

22.

Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108(2):193–199. doi:10.1016/0378-1119(91)90434-D CrossRefPubMed

23.

Sakaguchi M, Urakawa T, Hirayama Y et al (1993) Marek’s disease virus protein kinase gene identified within the short unique region of the viral genome is not essential for viral replication in cell culture and vaccine-induced immunity in chickens. Virology 195(1):140–148. doi:10.1006/viro.1993.1354 CrossRefPubMed

24.

Sakaguchi M, Hirayama Y, Maeda H et al (1994) Construction of recombinant Marek’s disease virus type 1 (MDV1) expressing the Escherichia coli lacZ gene as a possible live vaccine vector: The US10 gene of MDV1 as a stable insertion site. Vaccine 12(10):953–957. doi:10.1016/0264-410X(94)90040-X CrossRefPubMed

25.

Sakaguchi M, Nakamura H, Sonoda K et al (1998) Protection of chickens with or without maternal antibodies against both Marek’s and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek’s disease virus type 1. Vaccine 16(5):472–479. doi:10.1016/S0264-410X(97)80001-1 CrossRefPubMed

26.

Sharma JM, Kim IJ, Rautenschlein S, Yeh HY (2000) Infectious bursal disease virus of chickens: pathogenesis and immunosuppression. Avian Dis 24(2–3):223–235. doi:10.1016/S0145-305X(99)00074-9

27.

Skinner MA, Laidlaw SM, Eldaghayes I et al (2005) Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 4(1):63–76. doi:10.1586/14760584.4.1.63 CrossRefPubMed

28.

Sonoda K, Sakaguchi M, Matsuo K et al (1996) Asymmetric deletion of the junction between the short unique region and the inverted repeat does not affect viral growth in culture and vaccine-induced immunity against Marek’s disease. Vaccine 14(4):277–284. doi:10.1016/0264-410X(95)00210-R CrossRefPubMed

29.

Sonoda K, Sakaguchi M, Okamura H et al (2000) Development of an effective polyvalent vaccine against both Marek’s and Newcastle diseases based on recombinant Marek’s disease virus type 1 in commercial chickens with maternal antibodies. J Virol 74(7):3217–3226. doi:10.1128/JVI.74.7.3217-3226.2000 CrossRefPubMedPubMedCentral

30.

Takase K, Uchimura T, Katsuki N, Yamamoto M (1993) Agar gel precipitin line patterns and pathogenicity of infectious bursal disease viruses. J Vet Med Sci 55(1):137–139. doi:10.1292/jvms.55.137 CrossRefPubMed

31.

Takase K, Baba GM, Ariyoshi R, Fujikawa H (1996) Susceptibility of chicken embryos to highly virulent infectious bursal disease virus. J Vet Med Sci 58(11):1129–1131. doi:10.1292/jvms.58.11_1129 CrossRefPubMed

32.

Tsukamoto K, Kojima C, Komori Y et al (1999) Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek’s disease virus (MDV) with a recombinant MDV expressing IBDV VP2. Virology 257(2):352–362. doi:10.1006/viro.1999.9641 CrossRefPubMed

33.

Tsukamoto K, Saito S, Saeki S et al (2002) Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens. J Virol 76(11):5637–5645. doi:10.1128/JVI.76.11.5637 CrossRefPubMedPubMedCentral

34.

van den Berg TP (2000) Acute infectious bursal disease in poultry: a review. Avian Pathol 29(3):175–194. doi:10.1080/03079450050045431 CrossRefPubMed

35.

Witter RL, Nazerian K, Purchase HG, Burgoyne GH (1970) Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek’s disease virus. Am J Vet Res 31(3):525–538PubMed

36.

Witter RL (1972) Turkey herpesvirus: lack of oncogenicity for turkeys. Avian Dis 16(3):666–670. doi:10.2307/1588684 CrossRefPubMed

37.

Witter RL, Solomon JJ (1972) Experimental infection of turkeys and chickens with a herpesvirus of turkeys (HVT). Avian Dis 16(1):34–44. doi:10.2307/1588897 CrossRefPubMed

38.

Wyeth PJ, O’Brien JDP, Cullen GA (1981) Improved performance of progeny of broiler parent chickens vaccinated with infectiou bursal disease oil-emulsion vaccine. Avian Dis 25(1):228–241. doi:10.2307/1589849 CrossRefPubMed

39.

Yamazaki K, Ohta H, Kawai T et al (2016) Characterization of variant infectious bursal disease virus from a broiler farm in Japan using immunized sentinel chickens. J Vet Med Sci. doi:10.1292/jvms.16-0301

40.

Zhang F, Chen W, Ma C et al (2014) Transcriptional activity comparison of different sites in recombinant Marek’s disease virus for the expression of the H9N2 avian influenza virus hemagglutinin gene. J Virol Methods 207:138–145. doi:10.1016/j.jviromet.2014.07.011 CrossRefPubMed

41.

Zhao W, Spatz S, Zhang Z et al (2014) Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges. J Virol 88(15):8397–8406. doi:10.1128/JVI.01321-14 CrossRefPubMedPubMedCentral

Title: Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody-eliciting capacity and is suitable for the establishment of a recombinant vaccine
Authors: Kiyohiko Andoh
Kenichi Yamazaki
Yoko Honda
Takashi Honda
Publication date: 01-04-2017
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 4/2017
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-016-3181-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody-eliciting capacity and is suitable for the establishment of a recombinant vaccine

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

A novel East African monopartite begomovirus-betasatellite complex that infects Vernonia amygdalina

Evidence of independent evolution of genotype XIII Newcastle disease viruses in India

Genetic characterization of a second novel picornavirus from an amphibian host, smooth newt (Lissotriton vulgaris)

Identification of novel Newcastle disease virus sub-genotype VII-(j) based on the fusion protein

Restricted replication of viral hemorrhagic septicemia virus (VHSV) in a birnavirus-carrier cell culture

AKT capture by feline leukemia virus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page